10-QPeriod: Q3 FY2007

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q3 Ended Sep 30, 2007

Filed November 9, 2007For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. reported a significant increase in net loss for the nine months ended September 30, 2007, reaching $305.5 million compared to $179.5 million in the same period of 2006. This was driven by substantial investments in research and development, particularly for its lead drug candidate, telaprevir, which is in Phase 2b clinical trials for Hepatitis C. The company is actively building its capabilities for late-stage development and potential commercialization, reflecting a strategic shift towards greater internal control over its drug pipeline. Despite the widening net loss, Vertex Pharmaceuticals maintained a solid cash position with $514.5 million in cash, cash equivalents, and marketable securities at the end of the third quarter of 2007. The company has also eliminated its convertible debt during this period. Management anticipates continued operating losses and plans to pursue additional capital transactions to fund its ongoing development activities, especially for telaprevir, as it prepares for potential regulatory approval and market launch.

Key Highlights

  • 1Net loss for the nine months ended September 30, 2007, increased to $305.5 million from $179.5 million in the prior year period.
  • 2Research and Development expenses surged by 51% to $397.7 million for the nine months ended September 30, 2007, reflecting significant investment in drug development, particularly for telaprevir.
  • 3The company held $514.5 million in cash, cash equivalents, and marketable securities as of September 30, 2007, indicating a strong liquidity position.
  • 4Vertex Pharmaceuticals has eliminated all convertible debt by repaying its 2007 notes and through the conversion of its 2011 notes into common stock.
  • 5Interim data from Phase 2b trials for telaprevir showed promising sustained viral response (SVR) rates, with 61% in PROVE 1 and 65% in PROVE 2 for certain treatment arms.
  • 6The company is increasing investment in commercial supply for telaprevir in preparation for potential market launch, acknowledging the associated risks if regulatory approval is not obtained.
  • 7Vertex Pharmaceuticals expects to continue incurring substantial operating losses and plans to raise additional funds through capital markets and other financing strategies.

Frequently Asked Questions

The primary driver for the increased net loss is the substantial rise in research and development (R&D) expenses. This increase is due to significant investments in advancing drug candidates through clinical trials, particularly telaprevir for Hepatitis C, and building the commercial supply chain in preparation for potential market launch.

Vertex Pharmaceuticals maintains a strong liquidity position, reporting $514.5 million in cash, cash equivalents, and marketable securities as of September 30, 2007. The company plans to continue raising significant funding through capital market transactions, collaborative agreements, and other financing strategies to support its ongoing operations and development activities, as it expects to incur further operating losses.

Vertex presented interim data from its Phase 2b trials (PROVE 1 and PROVE 2) for telaprevir. These trials showed promising sustained viral response (SVR) rates in specific treatment arms. The company is in discussions with regulatory authorities regarding future trials and is investing significantly in preparing for Phase 3 development and potential commercialization, while acknowledging the inherent risks.

Yes, Vertex Pharmaceuticals has eliminated its outstanding convertible debt. The company repaid its 5% Convertible Subordinated Notes due in 2007 and, in early 2007, holders of its 5.75% Convertible Senior Subordinated Notes due in 2011 converted these notes into common stock.